New strategy to include CML alongside AML

Mendus has announced a strategy update, unveiling plans to expand the application of vididencel beyond the current lead programme in acute myeloid leukaemia (AML), to chronic myeloid leukaemia (CML). Following encouraging preclinical results in CML, presented at ASH 2024, Mendus’s clinical strategy will now pursue vididencel in this indication. A Phase Ia/Ib trial is being prepared to evaluate safety and feasibility, with first data expected in mid-2026. In parallel, in AML, Mendus has planned a Phase Ib trial to assess vididencel in combination with azacitidine and venetoclax in chemo-unfit patients, to run alongside the ongoing Phase II CADENCE trial (vididencel in combination with azacitidine only; now recruited 12 patients for part 1...